Abciximab biosimilar (Reliance Life Sciences)

阿昔单抗生物类似物 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAbciximab biosimilar (Reliance Life Sciences)
Drug Alias Nameabciximab biosimilar阿昔单抗生物仿制药 (Reliance Life Sciences)AbcixiRelR-TPR-019
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsAngina, UnstableMyocardial Ischemia
Global Approved IndicationsAngina, UnstableMyocardial Ischemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2013/01/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life SciencesMedicure Inc
Inactive CompaniesN/A
Active IndicationsAngina, UnstableMyocardial Ischemia
Inactive IndicationsN/A

Other Information

ATC CodeB01AC13
Related LinksN/A